Trillium Asset Management’s Novo Nordisk NVO Stock Holding History

Trillium Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$944K	Sell	19,689 -125,913	-86%	-$5.41M	0.03%	167
2026 Q1	$5.86M	Sell	145,602 -21,732	-13%	-$1.03M	0.19%	104
2025 Q4	$8.62M	Sell	167,334 -21,822	-12%	-$1.12M	0.26%	90
2025 Q3	$10.5M	Sell	189,156 -1,807	-0.9%	-$106K	0.28%	87
2025 Q2	$13.2M	Sell	190,963 -8,472	-4%	-$576K	0.35%	77
2025 Q1	$13.8M	Sell	199,435 -32,731	-14%	-$2.7M	0.4%	75
2024 Q4	$20M	Sell	232,166 -4,231	-2%	-$458K	0.52%	65
2024 Q3	$28.1M	Sell	236,397 -882	-0.4%	-$118K	0.69%	48
2024 Q2	$33.9M	Sell	237,279 -3,325	-1%	-$441K	0.86%	34
2024 Q1	$30.9M	Sell	240,604 -3,239	-1%	-$386K	0.79%	43
2023 Q4	$25.2M	Sell	243,843 -5,423	-2%	-$536K	0.69%	50
2023 Q3	$22.7M	Sell	249,266 -51,268	-17%	-$4.52M	0.68%	51
2023 Q2	$24.3M	Sell	300,534 -52,032	-15%	-$4.25M	0.68%	52
2023 Q1	$29.3M	Sell	352,566 -3,338	-0.9%	-$237K	0.86%	41
2022 Q4	$24.1M	Sell	355,904 -2,262	-0.6%	-$133K	0.74%	45
2022 Q3	$17.8M	Sell	358,166 -1,306	-0.4%	-$70K	0.58%	66
2022 Q2	$20.1M	Buy	359,472 +36,288	+11%	+$2.01M	0.62%	60
2022 Q1	$17.9M	Buy	323,184 +136,540	+73%	+$7.01M	0.48%	77
2021 Q4	$10.5M	Buy	186,644 +10,190	+6%	+$552K	0.25%	100
2021 Q3	$8.47M	Buy	176,454 +160,264	+990%	+$7.75M	0.22%	103
2021 Q2	$678K	Hold	16,190	–	–	0.02%	191
2021 Q1	$546K	Hold	16,190	–	–	0.02%	199
2020 Q4	$565K	Sell	16,190 -718	-4%	-$24.8K	0.02%	199
2020 Q3	$587K	Hold	16,908	–	–	0.02%	184
2020 Q2	$554K	Sell	16,908 -3,870	-19%	-$123K	0.02%	191
2020 Q1	$625K	Hold	20,778	–	–	0.03%	183
2019 Q4	$601K	Sell	20,778 -3,400	-14%	-$94.1K	0.03%	198
2019 Q3	$625K	Buy	24,178 +4,510	+23%	+$114K	0.03%	204
2019 Q2	$502K	Hold	19,668	–	–	0.02%	196
2019 Q1	$514K	Sell	19,668 -90	-0.5%	-$2.21K	0.03%	202
2018 Q4	$455K	Sell	19,758 -2,910	-13%	-$64.7K	0.03%	199
2018 Q3	$534K	Hold	22,668	–	–	0.03%	199
2018 Q2	$523K	Sell	22,668 -1,004	-4%	-$23.9K	0.03%	197
2018 Q1	$583K	Buy	23,672 +874	+4%	+$22.9K	0.03%	193
2017 Q4	$612K	Hold	22,798	–	–	0.03%	187
2017 Q3	$549K	Sell	22,798 -1,058	-4%	-$23.9K	0.03%	186
2017 Q2	$512K	Buy	23,856 +96	+0.4%	+$1.94K	0.03%	191
2017 Q1	$407K	Sell	23,760 -48,524	-67%	-$845K	0.03%	187
2016 Q4	$1.3M	Sell	72,284 -2,680	-4%	-$48.6K	0.09%	161
2016 Q3	$1.56M	Sell	74,964 -4,268	-5%	-$106K	0.1%	151
2016 Q2	$2.13M	Sell	79,232 -15,846	-17%	-$435K	0.14%	145
2016 Q1	$2.58M	Sell	95,078 -35,928	-27%	-$963K	0.17%	137
2015 Q4	$3.8M	Buy	131,006 +39,996	+44%	+$1.11M	0.26%	119
2015 Q3	$2.47M	Buy	91,010 +1,596	+2%	+$45.2K	0.17%	131
2015 Q2	$2.45M	Buy	89,414 +10,408	+13%	+$293K	0.16%	138
2015 Q1	$2.11M	Buy	79,006 +4,150	+6%	+$95.6K	0.14%	138
2014 Q4	$1.58M	Buy	74,856 +352	+0.5%	+$7.86K	0.11%	150
2014 Q3	$1.77M	Buy	74,504 +1,718	+2%	+$39.5K	0.15%	130
2014 Q2	$1.68M	Buy	72,786 +8,614	+13%	+$190K	0.14%	134
2014 Q1	$1.47M	Sell	64,172 -130,518	-67%	-$2.78M	0.14%	133
2013 Q4	$3.6M	Sell	194,690 -106,940	-35%	-$1.86M	0.35%	103
2013 Q3	$5.1M	Sell	301,630 -40,300	-12%	-$678K	0.57%	76
2013 Q2	$5.3M	Buy	+341,930	New	+$5.69M	0.65%	65

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Trillium Asset Management's NVO Position: Q2 2026 in Review

Trillium Asset Management reduced its Novo Nordisk (NVO) stake by 86% in Q2 2026, selling an estimated $5.41M and leaving 19,689 shares worth $944K. The position accounts for 0.03% of the portfolio, ranked #167.

Trillium Asset Management first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $33.9M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Trillium Asset Management held 19,689 shares of Novo Nordisk worth $944K as of Q2 2026.
Trillium Asset Management sold 125,913 Novo Nordisk shares in Q2 2026, an estimated $5.41M.
Novo Nordisk made up 0.03% of Trillium Asset Management's portfolio in Q2 2026, its #167 holding.
Trillium Asset Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Trillium Asset Management's Novo Nordisk position peaked at $33.9M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Trillium Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.